Finerenone vs SGLT2 inhibitors
Finerenone is a non-steroidal mineralocorticoid receptor antagonist. SGLT2 inhibitors such as dapagliflozin and empagliflozin are oral glucose-lowering drugs. Both are used to protect the kidneys and heart in people with type 2 diabetes and chronic kidney disease, and they act in different ways, so they are often discussed together rather than as rivals.
What our reports show
No report in our library compared finerenone with SGLT2 inhibitors head to head. The one report that covers both is a network meta-analysis in CKD with type 2 diabetes, which compared them indirectly through placebo. It used ten trial datasets.
Versus placebo, both classes lowered the hazard of kidney function progression. The HR was 0.64 (95% CI: 0.56-0.73) for SGLT2 inhibitors and 0.84 (95% CI: 0.77-0.92) for finerenone. Both also lowered heart-failure hospitalisation, with an HR of 0.61 (95% CI: 0.53-0.69) for SGLT2 inhibitors and 0.78 (95% CI: 0.66-0.92) for finerenone.
In the indirect comparison, SGLT2 inhibitors were favoured for kidney function progression (HR 0.76, 95% CI: 0.64-0.90) and heart-failure hospitalisation (HR 0.77, 95% CI: 0.63-0.95). Atherothrombotic events and mortality did not differ significantly. The heart-failure contrast did not persist in dedicated CKD trials. Finerenone increased hyperkalaemia without increasing acute kidney injury.
These figures should be read with care. The authors rated certainty as low or very low for every between-class comparison. They call the differences hypothesis-generating and say they should not be used to rank the agents. The network has no closed loops, and the authors say transitivity cannot be verified. So it is not known whether the trial populations were similar enough for a fair indirect comparison. The authors conclude that the two classes appear complementary rather than interchangeable. The abstract does not address combined use.
Written only from the reports below and checked against them. Updated 13 November 2026.
Studies that looked at both
- Network meta-analysis: SGLT2 inhibitors versus finerenone in CKD with type 2 diabetesMeta-analysis · 14 October 2026
Finerenone
No reports yet.
SGLT2 inhibitors
- Real-world cohort: SGLT-2 inhibitors linked to lower kidney failure risk than GLP-1 RAsCohort study · 4 November 2026
- SGLT2 inhibitors in adults aged 75 and over: cohort finds no increased harm versus DPP-4 inhibitorsCohort study · 28 October 2026
- SGLT2 inhibitor use associated with small rises in haemoglobin and haematocrit, 85 trialsMeta-analysis · 26 October 2026
- Oral GLP-1 agonist HRS-7535 lowered HbA1c in Phase II trial in type 2 diabetesRandomised trial · 18 October 2026
- Oral orforglipron vs dapagliflozin on metformin: ACHIEVE-2 HbA1c results postedTrial registry · 18 October 2026
- Meta-analysis: SGLT2 inhibitors reduce heart failure or CV death in type 2 diabetesMeta-analysis · 14 October 2026
- ADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabetesGuideline · 10 October 2026
- Oral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in ChinaRandomised trial · 10 October 2026
For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 4 November 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.